Healthy Skepticism Library item: 6272

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Ridley DB, Grabowski HG, Moe JL.
Developing drugs for developing countries.
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):313-24
http://content.healthaffairs.org/cgi/content/full/25/2/313

Abstract:

Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a “priority review voucher.” The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.

Keywords:
Anti-Infective Agents/economics Anti-Infective Agents/supply & distribution Antiparasitic Agents/economics Antiparasitic Agents/supply & distribution Developing Countries* Drug Approval/economics Drug Approval/legislation & jurisprudence* Drug Industry/economics* Health Services Accessibility/economics Humans Legislation, Drug Marketing Orphan Drug Production/economics* Patents Program Development Reimbursement, Incentive Research Support, Non-U.S. Gov't United States United States Food and Drug Administration